Company intelligence / Profile preview

Novira Therapeutics

Radnor, Pennsylvania, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~49
Development stage: Phase 1

Overview

Novira Therapeutics developed first-in-class antiviral therapeutics targeting viral capsid proteins for the treatment of chronic HBV and HIV infections. Their oral drugs offered a promising treatment option both as monotherapy and in combination with current standards of care[4].

Therapeutic areas: Infectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

NVR 3-778

Phase 1

Indications: Chronic hepatitis B

Beyond the preview

Go deeper on Novira Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novira Therapeutics.

Explore the full profile